newsfilter
← Latest News
Business Wire·

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, and Gerald